As Medicare drug price negotiations move from policy theory to real-world implementation, stakeholders across the healthcare system are feeling the impact. Chelsea and Logan unpack what MFP means for drug manufacturers, hospitals, providers, patients, and the 340B program, and explore early reactions, operational challenges, and what comes next.

Whether you work in health policy, pharmaceutical pricing, hospital administration, or government affairs, this episode delivers a clear, insightful update on one of the most significant drug pricing reforms in decades.

Stay informed on the policies shaping the future of healthcare.

👉 Subscribe to the 340Banter Podcast for weekly insights on 340B, drug pricing reform, healthcare legislation, and pharmaceutical policy.